# OBiO Technology

Shanghai cell-and-gene-therapy CRO/CDMO (SSE STAR Market 688238) packaging plasmid, AAV, lentiviral and adenoviral vectors from research grade through GMP Phase I-III to commercial supply, alongside cell-processing and regenerative-medicine services.


Source: https://en.bioecon.ru/companies/obio-technology/
Updated: 2026-09-18

- Country: China
- Ticker: SSE STAR: 688238

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 2013 | https://www.obiosh.com/ |
| Headquarters | Shanghai, China | https://www.obiosh.com/ |
| Funding | Listed on the SSE STAR Market, stock code 688238 | https://q.stock.sohu.com/cn/688238/index.shtml |
| Regulatory approval | Holds the drug manufacturing licence (Category C); reported a fully commercial closed loop in July 2026 | https://www.obiosh.com/ |
| Capacity | GMP production spanning Phase I/II/III to commercial stage for plasmid, AAV, adenovirus and other viral vectors | https://www.obiosh.com/ |

Independent sources: q.stock.sohu.com

## Technologies

- [Adenoviral vector gene therapy](https://en.bioecon.ru/technology/adenoviral-vector-gene-therapy/)